scholarly journals A Phase 1 Study of a Recombinant Viruslike Particle Vaccine against Human Papillomavirus Type 11 in Healthy Adult Volunteers

2001 ◽  
Vol 183 (10) ◽  
pp. 1485-1493 ◽  
Author(s):  
Thomas G. Evans ◽  
William Bonnez ◽  
Robert C. Rose ◽  
Scott Koenig ◽  
Lisa Demeter ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Healthy Adult ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Viruslike Particle ◽  
Adult Volunteers

scholarly journals A Passive Vaccine Approach to Respiratory Syncytial Virus Prophylaxis for All Infants: Results of a Phase 1 Study in Healthy Adult Volunteers

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
M. Pamela Griffin ◽  
Anis A. Khan ◽  
Kathryn M. Jensen ◽  
Therese F. Takas ◽  
Filip Dubovsky ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Healthy Adult ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Syncytial Virus ◽  
Vaccine Approach ◽  
Adult Volunteers

A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers

Biologicals ◽  
2017 ◽  
Vol 50 ◽  
pp. 81-86 ◽  
Author(s):  
Raburn M. Mallory ◽  
S.Omar Ali ◽  
Therese Takas ◽  
Martin Kankam ◽  
Filip Dubovsky ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Influenza A ◽  
Healthy Adult ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Adult Volunteers

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Anti-Staphylococcal Lysin, LSVT-1701, in Healthy Adult Subjects

2022 ◽  
Author(s):  
Mary Beth Wire ◽  
Soo Youn Jun ◽  
In-Jin Jang ◽  
Seung-Hwan Lee ◽  
Jun Gi Hwang ◽  
...  
Keyword(s):  
Healthy Adult ◽  
Phase 1 ◽  
Infusion Site ◽  
Healthy Male ◽  
C Reactive Protein ◽  
Phase 1 Study ◽  
Reactive Protein ◽  
Male Subjects ◽  
Common Teaes ◽  
Dose Proportional

Thirty-two healthy male subjects (8 per cohort) were randomized 6:2 to active:placebo. LSVT-1701, an anti-staphylococcal lysin, was administered intravenously as a 6 mg/kg single dose and as 1.5, 3, and 4.5 mg/kg twice daily for 4 days. LSVT-1701 exposure increased in a greater than dose proportional manner and did not accumulate. Treatment-emergent adverse events (TEAEs) were predominantly of mild intensity. The most common TEAEs were chills, pyrexia, headache, infusion site events, cough, rhinorrhea, and increases in C-reactive protein.

Sign in / Sign up

Export Citation Format

Share Document